Elevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug.
Bogari NM, Aljohani A, Amin AA, Al-Allaf FA, Dannoun A, Taher MM, Elsayed A, Rednah DI, Elkhatee O, Porqueddu M, Alamanni F, Khogeer SAA, Fawzy A. A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug. BMC Cardiovasc Disord 2019 Jan 3;19(1):2.